You’re invited to IPO Readiness 2026: The New Bar for Life Sciences & Health Care, a webinar hosted by Deloitte & Touche LLP featuring guest speakers from Wilson Sonsini Goodrich & Rosati and J.P. Morgan.
With IPO activity increasing in 2025 and early 2026 indicators remaining consistent, this session will cover what “IPO-ready” looks like now in life science & health care industries.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
Copyright © 2026 Deloitte Development LLC. All rights reserved.
In light of renewed initial public offering (IPO) activity across the life sciences and health care sectors and expectations for a selective continuation into 2026—Deloitte will cohost a 1.5-hour virtual CPE program. The session will discuss recent market dynamics and how issuer readiness expectations have evolved, with investor interest often emphasizing more mature companies with clearer clinical and/or commercial traction.
Click here to access the NASBA Sponsor Statement
CPE credit is only awarded for participation in the live program, and not a recording of the presentation.
Disclaimer: Technological difficulties and/or user errors renders an offering or an individual ineligible for CPE credit.
CPE certificates for eligible viewers are emailed 4-6 weeks following the conclusion of the live webinars.
*NASBA CPE Credits are not guaranteed. Receipt of NASBA CPE Credits for this course is contingent upon eligibility of course subject matter, course owner satisfaction of course delivery and submission requirements, and instructor/participant satisfaction of attendance proof requirements. Deliveries of this course by a non-U.S. Deloitte member firm are not eligible for NASBA CPE Credits.
CPE credit is only awarded for participation in the live program, and not a recording of the presentation.
Disclaimer: Technological difficulties and/or user errors renders an offering or an individual ineligible for CPE credit.
CPE certificates for eligible viewers are emailed 4-6 weeks following the conclusion of the live webinars.
Click here to access the NASBA Sponsor Statement
We encourage you to join using your laptop or phone video camera. An audio and/or visual warning will be provided upon entering the meeting and once recording commences. If you continue to participate in the meeting following this warning, your participation will serve as your express consent to such recording. Participant names may also be visible to all who join.
Moyan is a Senior Manager in Deloitte’s National Office, advising public and private companies on complex accounting and auditing matters. With nine years of Audit & Assurance experience, Moyan focuses on the life sciences, biotech, and broader health care ecosystem, including emerging growth companies preparing for the public markets. Over the last two years, Moyan has supported two biotech IPO readiness and execution efforts, helping management teams navigate technical accounting considerations, audit readiness, and SEC reporting expectations.
Based in Seattle, Moyan is also actively involved in the local life sciences and biotech community, convening events that strengthen connections across founders, investors, and industry leaders.
B.J. Spence currently leads Deloitte’s Technical Accounting & Reporting (TAR) practice for the Life Sciences industry and also serves as US Life Sciences Capital Markets Co-Leader. In these roles, B.J. is responsible for overseeing the execution and delivery of services that are targeted at helping CFOs and Controllers solve their most complex and challenging projects, including IPO/SPAC readiness and execution.
B.J. has extensive experience over 18 years of working with a wide array of public and private companies of all sizes and across all industries. This includes serving as a trusted advisor to the individuals in the accounting and finance departments at these companies and supporting them as they prepare to enhance their financial statements, business processes, controls, and overall organization as they adapt to challenges commonly faced when navigating U.S. GAAP, SEC, and auditor requirements.
Bryan King is a partner in the Seattle office of Wilson Sonsini Goodrich & Rosati. His practice focuses on corporate and securities law matters for emerging growth companies, venture capital firms, and public companies.
Bryan has advised notable companies and investment banks such as Alpine Immune Sciences, LeonaBio, NanoString Technologies, Xenon Pharmaceuticals, Zymeworks, BofA Securities, Goldman Sachs, J.P. Morgan, and Morgan Stanley. In addition to being a corporate partner at the firm, Bryan previously served as corporate counsel to a biopharmaceutical company.
Michael Nordtvedt currently leads the capital markets practice at Wilson Sonsini Goodrich & Rosati and is a partner at the firm’s Seattle and Palo Alto offices, where he focuses on the representation of public and private technology, medical device, and life sciences companies through all stages of their growth, as well as investment banks and venture capital and private equity firms.
Michael specializes in corporate and securities law, including general corporate representation, public offerings, private placements, and mergers and acquisitions. He also has considerable experience in counseling companies on complex governance, securities laws and disclosure issues.
Adi Jayanthi is an Executive Director in J.P. Morgan’s Healthcare Investment Banking Group, based in Seattle. He joined J.P. Morgan’s New York office approximately eight years ago and holds global coverage responsibilities across large pharmaceutical and emerging biotechnology companies. During his tenure at J.P. Morgan, Adi has advised clients on more than 60 mergers and acquisitions and financing transactions, representing over $60 billion in aggregate value.
Prior to joining J.P. Morgan, Adi spent approximately five years as a management consultant at ZS Associates, based in Germany and previously in New York. He holds a B.S. in Engineering and Mathematics from the University of Pennsylvania and an M.B.A. from Northwestern University’s Kellogg School of Management.
